FDA found SterRx, acquired by Sagent, made sterile drugs under conditions that risked contamination and lacked sterility assurance.
What happened
FDA inspected the SterRx facility in Plattsburgh, NY, from September 21 to November 4, 2021. Investigators found serious deficiencies in sterile processing, including blocked or turbulent first air, dirty equipment, and inadequate environmental monitoring. The firm stopped sterile production and recalled certain sterile lots because of lack of sterility assurance.
What FDA found
FDA said first air was blocked or not provided in ISO 5 cleanroom areas where open IV bags and sterile closures were handled.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]Smoke studies showed turbulent, non-laminar air in an ISO 5 cleanroom zone near IV bag filling and sealing.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]The firm did not adequately evaluate or correct microbial contamination found in the ISO 5 sterile processing area.
21 CFR 211.42(c)(10)(iv)Equipment in classified areas was visibly dirty and hard to clean, with rust, chipped paint, tape, and residue buildup.
21 CFR 211.67(a)Sterilized equipment and utensils were stored in an unclassified transition area without an established hold time.
FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]FDA said the firm failed to ensure container closure systems protected the drug product from contamination.
21 CFR 211.94(b)
What FDA wants
FDA asks the company to reply in writing within 15 working days with specific steps taken to address the violations, or to say that it does not intend to resume sterile drug production. If it cannot fully respond in that time, it must give the reason and a timeline.
Who should pay attention
- hospitals and clinics that buy compounded sterile drugs
- outsourcing facilities and sterile compounders
- distributors or brands relying on SterRx/Sagent sterile products
This is a summary. Read the original letter on fda.gov.